{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T22:12:07Z","timestamp":1771625527267,"version":"3.50.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The treatment of chronic myeloid leukemia through tyrosine kinase inhibitors (TKIs) has achieved promising efficacy and safety outcomes, however the costs are associated with a substantial economic burden. The objective of this study was to develop a Markov model with a 20-year time horizon to assess the cost effectiveness of TKIs from a public healthcare system perspective in South Africa.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We constructed a Markov model to compare three strategies in which treatment was initiated with either imatinib, nilotinib, or dasatinib. Treatment was switched to another TKI in the case of intolerance or resistance to the initial TKI. Effectiveness and utility data were obtained from published literature. Cost data was obtained from local sources for generic imatinib and branded second-generation TKIs and based on national tariffs. Outcomes were reported in total costs and quality-adjusted life years (QALYs). Outcomes were based on calculated incremental cost effectiveness ratios (ICERs) and compared to a willingness-to-pay (WTP) threshold. Sensitivity analyses were conducted to determine the robustness of the model outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The base-case results showed that imatinib was favored over nilotinib and dasatinib by having the lowest cost at $120 719.55 and providing 5.93 QALYs. Compared to imatinib strategy, nilotinib had an ICER of $26 620.27 per QALY and dasatinib had an ICER of $35 934.94 per QALY, both exceeding the WTP threshold of $18 760 per QALY gained. The sensitivity analysis indicated the robustness of the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Imatinib remains the most cost-effective first-line treatment for adults diagnosed with CML in South Africa, with a high probability of being cost-effective across a range of WTP thresholds. Nilotinib and Dasatinib, though offering clinical benefits, their affordability remains a challenge within the current healthcare system and should remain reserved for second-line treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1511603","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:28:53Z","timestamp":1736227733000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa"],"prefix":"10.3389","volume":"15","author":[{"given":"Rochelle","family":"Woudberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edina","family":"Sinanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","article-title":"Uniform patient fee schedule tarriffs 2024: tshwane","author":"Africa","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40273-022-01189-9","article-title":"A systematic literature review of the economic evaluations of treatments for patients with chronic myeloid leukemia","volume":"40","author":"Agrawal","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1182\/blood.v118.21.745.745","article-title":"Clinical significance of complete cytogenetic response (CCyR) and major molecular response (MMR) achieved with different treatment modalities used as frontline therapy in chronic myeloid leukemia (CML) chronic phase (CP)","volume":"118","author":"Alattar","year":"2011","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B7","volume-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","year":"2015"},{"key":"B8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2147\/DDDT.S191303","article-title":"Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities","volume":"13","author":"Flis","year":"2019","journal-title":"Drug Des. Devel Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s40261-018-0706-5","article-title":"Economic evaluations of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in middle- and high-income countries: a systematic review","volume":"38","author":"Fu","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"B10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrclinonc.2016.59","article-title":"Targeted therapy: generic imatinib - impact on frontline and salvage therapy for CML","volume":"13","author":"Gorkin","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B11","article-title":"Database of medicine prices 30 august 2024","author":"Health","year":"2024"},{"key":"B12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40258-019-00489-0","article-title":"Cost effectiveness of the third-generation tyrosine kinase inhibitor (TKI) ponatinib, vs. Second-generation TKIs or stem cell transplant, as third-line treatment for chronic-phase chronic myeloid leukemia","volume":"17","author":"Hirt","year":"2019","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4161\/cc.10.2.14537","article-title":"Impact of BCR-ABL mutations on patients with chronic myeloid leukemia","volume":"10","author":"Hochhaus","year":"2011","journal-title":"Cell Cycle"},{"key":"B14","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"Hoglund","year":"2015","journal-title":"Ann. Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","article-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am. J. Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/ajh.23180","article-title":"Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am. J. Hematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B20","first-page":"2167","article-title":"Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate","volume":"8","author":"Kantarjian","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jval.2017.12.016","article-title":"Use and misuse of cost-effectiveness analysis thresholds in low- and middle-income countries: trends in cost-per-DALY studies","volume":"21","author":"Leech","year":"2018","journal-title":"Value Health"},{"key":"B24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40261-017-0587-z","article-title":"Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China","volume":"38","author":"Li","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"B25","first-page":"840","article-title":"Recommendations for the management of adult chronic myeloid leukaemia in South Africa","volume":"101","author":"Louw","year":"2011","journal-title":"S Afr. Med. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s40273-014-0177-3","article-title":"Model-based cost-effectiveness analyses for the treatment of chronic myeloid leukaemia: a review and summary of challenges","volume":"32","author":"Marsh","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1185\/03007995.2015.1120189","article-title":"Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia","volume":"32","author":"McGarry","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"B28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.canep.2013.01.002","article-title":"Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries","volume":"37","author":"Mendizabal","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"B29","volume-title":"NHLS State price list 2018","year":"2018"},{"key":"B30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-020-00185-z","article-title":"Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study","volume":"9","author":"Ning","year":"2020","journal-title":"Exp. Hematol. & Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"djw003","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"B32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16420","article-title":"Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses","volume":"16","author":"Pavey","year":"2012","journal-title":"Health Technol. Assess."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2165\/00019053-200826050-00007","article-title":"Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia","volume":"26","author":"Reed","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"982395","DOI":"10.1155\/2015\/982395","article-title":"Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States: a decision analysis","volume":"2015","author":"Rochau","year":"2015","journal-title":"Leuk. Res. Treat."},{"key":"B37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40258-013-0071-8","article-title":"Systematic assessment of decision-analytic models for chronic myeloid leukemia","volume":"12","author":"Rochau","year":"2014","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B38","article-title":"State patient price list 2023-2024","year":"2024"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.v99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1016\/S2352-3026(19)30087-0","article-title":"Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study","volume":"6","author":"Shih","year":"2019","journal-title":"Lancet Haematol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4102\/sajo.v4i0.158","article-title":"Chronic myeloid leukaemia in the South African public health setting: Are we reaching the European LeukemiaNet targets for frontline therapy? South African","volume":"4","author":"Sikhipha","year":"2020","journal-title":"J. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.beha.2009.07.006","article-title":"The blast phase of chronic myeloid leukaemia","volume":"22","author":"Silver","year":"2009","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1524-4733.2009.00573.x","article-title":"A multinational study of health state preference values associated with chronic myelogenous leukemia","volume":"13","author":"Szabo","year":"2010","journal-title":"Value Health"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","article-title":"Diagnosis and treatment of chronic myeloid leukemia in 2015","volume":"90","author":"Thompson","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1017\/s0266462322000265","article-title":"Health Technology assessment in support of national health insurance in South Africa","volume":"38","author":"Wilkinson","year":"2022","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B46","doi-asserted-by":"publisher","first-page":"S447","DOI":"10.1016\/j.jval.2019.09.261","article-title":"PCN64 cost-effectiveness of imatinib since its introduction as first-line treatment in The Netherlands","volume":"22","author":"Wolters","year":"2019","journal-title":"Value Health"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1182\/bloodadvances.2019000745","article-title":"Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation","volume":"3","author":"Yamamoto","year":"2019","journal-title":"Blood Adv."},{"key":"B48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-140402","article-title":"Targeted literature review of patient reported outcomes (PROs) in chronic myeloid leukemia (CML) patients receiving second and later lines of treatment","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1511603\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:28:58Z","timestamp":1736227738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1511603\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":48,"alternative-id":["10.3389\/fphar.2024.1511603"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1511603","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1511603"}}